In a letter to FDA’s commissioner, Dr. Stephen Hahn, lawmakers from four states suggested it would be a “fool’s game” for the agency to try to keep kratom from consumers.
Four lawmakers from Arizona, Georgia, Utah and Nevada who sponsored kratom legislation in their states have requested a meeting with the top official of FDA—an agency that has long raised concerns about the safety of the botanical from Southeast Asia.
Positions held by FDA related to kratom and another botanical ingredient—CBD—were adopted long before Dr. Stephen Hahn was appointed commissioner, the lawmakers wrote to Hahn in a June 8 letter.